DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS The product is expected to be available in early August.
The FDA has given its approval to Suflave™, an osmotic laxative designed for colon cleansing prior to colonoscopy in adults. This marks a significant step in providing a low-volume preparation method with taste likened to a sports drink. The approval was rooted in robust clinical trials, focusing on efficacy and safety, leading to a promising alternative in colonoscopy preparation.
Key Points:
- Suflave, containing polyethylene glycol 3350 and various electrolytes, has been approved by the FDA as a colonoscopy preparation for adults.
- Two randomized, single-blind, active-controlled trials (Study 1 and Study 2) were the basis of the approval, with ClinicalTrials.gov Identifiers NCT04446299 and NCT04446312.
- 93% (Study 1) and 94% (Study 2) of patients receiving Suflave achieved successful bowel preparation, as rated by blinded endoscopists, compared with 89% and 94% for active comparators.
Additional Points:
- Suflave will be supplied in cartons containing 2 bottles and 2 lemon-lime flavor enhancing packets.
Conclusion:
- Suflave’s approval, reflecting a strong performance in clinical trials, brings a new, efficient option for colonoscopy preparation that emphasizes patient choice and improves the taste experience.
Gastroenterology Latest Posts
- Pancreatic Cancer Forms ‘Synapses,’ Scientists Discover
- FDA Approves First Pediatric IBS-C Treatment
- Trends in Cancer Incidence in Younger and Older Adults: An International Comparative Analysis
- Antibiotics and 6 Other Medications Linked to Disrupted Gut Microbiome
“We believe in patient choice and are committed to improving the colon preparation process for patients. We are delighted with the FDA’s approval of Suflave – which has efficacy equivalent to Suprep, but with taste similar to a sports drink.”
Alan Cooke
President and CEO
Sebela Pharmaceuticals
